The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids

Obesity Clinical Trial

Official title:

The Effect of Combining Cissus Quadrangularis and Irvingia Gabonensis on Obesity and Obesity Related Diseases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00526682
• Other study ID #: GHACT010
• Status: Completed
• Phase: N/A
• First received: September 6, 2007
• Last updated: September 6, 2007
• Start date: January 2007
• Est. completion date: April 2007

Study information

• Verified date: September 2007
• Source: Gateway Health Alliance
• Contact: n/a
• Is FDA regulated: No
• Health authority: Cameroon: Ministry of Public Health
• Study type: Interventional

Clinical Trial Summary

Hypothesis: Cissus quadrangularis as well as Irvingia gabonensis are used in weight management and related conditions. This study set out to investigate if a combination of the two could have additional benefits to overweight and obese people.

Description:

To assess and compare the effects of administration of Cissus quadrangularis (Linn) and a Cissus quadrangularis /Irvingia gabonensis combination on body weight blood pressure, fasting blood glucose, plasma total and LDL cholesterol in 72 overweight and obese subjects.

The study was a 10 week randomized, double-blind, placebo-controlled design, involving 72 obese or overweight participants. Participants were randomly divided into three groups (24 participants/ group):

Group 1 - Placebo; Group 2 - Cissus quadrangularis (CQ); Group 3 - Cissus quadrangularis and Irvingia gabonensis (CQ-IG).

The placebo (250mg) or active formulations ((150 mg CQ and 250 mg CQ-IG) were administered twice daily before meals. Weight as well as fasting blood was taken at baseline, and at 4, 8 and 10 weeks.

No major dietary changes or exercises were suggested during the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: April 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 19 Years to 55 Years

Eligibility

Inclusion Criteria:

• BMI>26kg/m2

Exclusion Criteria:

• Diabetics

• Pregnant and lactating

• Subjects on any other weight loss program

• Following any specific low calorie diet

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dyslipidemia
• Dyslipidemias
• Obesity
• Overweight

Intervention

Dietary Supplement:
• Irvingia/cissus combo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Gateway Health Alliance

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Weight change		10 weeks
Secondary	Blood lipids Body fat Fasting blood glucose		10 weeks